Dystonia Medical Research Foundation & Allergan Announce Partnership for Patient Programs

Community Events & Education Meetings Provide Information, Support, Hope in Recognition of September, Dystonia Awareness Month

Online PR News – 12-September-2015 – Chicago, IL – The Dystonia Medical Research Foundation (DMRF) and Allergan have announced the latest in a long history of partnerships on behalf of individuals and families impacted by dystonia, a neurological movement disorder. Allergan is supporting a number of community events and educational meetings designed to provide dystonia patients with the latest treatment and research information, and to create opportunities to bring members of the community together for support.

“We’re very grateful for Allergan’s continued generosity on behalf of the dystonia community,” says DMRF President Art Kessler. “We share the belief that access to accurate information is as critical to living well with dystonia as access to expert medical care. Being aware of the latest treatment and research information can transform lives. It is especially important during September, Dystonia Awareness Month.”

“Dystance4Dystonia Zoo Walks” are raising public awareness of dystonia in communities across the country. Teams of participants gather for a day at the zoo in support of a local family impacted by the disease. Upcoming Zoo Walks in 2015 will take place in Cleveland, Binghamton (NY), Pittsburgh, St. Louis, and Bronx (NY). Educational meetings featuring medical experts and sessions pertaining to coping with chronic illness are planned for the fall. More information about DMRF events will be available at www.dystonia-foundation.org.

Recognizing the urgent need for subspecialists trained in the diagnosis and treatment of dystonia, Allergan has also supported the DMRF’s Clinical Fellowship Training Program, which supports training of second-year physicians in preparation for a career in movement disorders with special expertise in dystonia.

Dystonia is a chronic, often disabling, movement disorder marked by extreme muscle contractions that cause involuntary movements and abnormal postures of the body and limbs. There are numerous subtypes that affect people of all ages and backgrounds. Common signs include twisting or abnormal movements of the head and neck, excessive blinking, a breathy or choking voice, hand cramps, or a twisted foot. Allergan’s biologic, Botox® (onabotulinumtoxinA), is a first-line treatment to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

The Dystonia Medical Research Foundation (DMRF) is a 501(c)(3) non-profit organization dedicated to advancing research for improved dystonia treatments and ultimately a cure, promoting awareness and patient education, and supporting the well-being of affected individuals and families. The DMRF can be reached at 800-377-3978 or www.dystonia-foundation.org.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. The Company is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. For more information, visit www.Allergan.com.